Mechanisms of bone metastases of breast cancer
Open Access
- 1 September 2009
- journal article
- review article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 16 (3) , 703-713
- https://doi.org/10.1677/ERC-09-0012
Abstract
Cancer development is a multi-step process driven by genetic alterations that elicit the progressive transformation of normal human cells into highly malignant derivatives. The altered cell proliferation phenotype of cancer involves a poorly characterized sequence of molecular events, which often result in the development of distant metastasis. In the case of breast cancer, the skeleton is among the most common of metastatic sites. In spite of its clinical importance, the underlying cellular and molecular mechanisms driving bone metastasis remain elusive. Despite advances in our understanding of the phenotype of cancer cells, the increased focus on the contribution of the tumor microenvironment and the recent revival of interest in the role of tumor-propagating cells (so called cancer stem cells) that may originate or be related to normal stem cells produced in the bone marrow, many important questions remain unanswered. As such, a more complete understanding of the influences of both the microenvironment and the tumor phenotype, which impact the entire multi-step metastatic cascade, is required. In this review, the importance of tumor heterogeneity, tumor-propagating cells, the microenvironment of breast cancer metastasis to bone as well as many current endocrine therapies for the prevention and treatment of metastatic breast cancer is discussed.Keywords
This publication has 79 references indexed in Scilit:
- Risks and benefits of bisphosphonatesBritish Journal of Cancer, 2008
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsPublished by Elsevier ,2008
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancerBritish Journal of Cancer, 2007
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 2007
- Beyond tumorigenesis: cancer stem cells in metastasisCell Research, 2006
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Inflammation and cancerNature, 2002
- Identification of the breast cancer susceptibility gene BRCA2Nature, 1995